Evidence map›Paper›PMID 31720991›Full record

ArticleInflammation2020

Improvement of Resveratrol Effects When Combined with Rice Oil in Rat Models of Inflammation.

Rodrigo B M Silva, Izaque S Maciel, Alice Ribeiro, Gabriel Rübensam, Andressa Bernardi, Fernanda B Morrone, Andre A Souto, Maria M Campos

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rodrigo B M SilvaEscola de Ciências da Saúde e da Vida, Centro de Pesquisa em Toxicologia e Farmacologia, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga, 6681, Partenon, Porto Alegre, RS, 90619-900, Brazil. rodrigo.braccinims@gmail.com.ORCID http://orcid.org/0000-0001-6284-7387
Izaque S MacielEscola de Ciências da Saúde e da Vida, Centro de Pesquisa em Toxicologia e Farmacologia, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga, 6681, Partenon, Porto Alegre, RS, 90619-900, Brazil.ORCID http://orcid.org/0000-0001-6597-5288
Alice RibeiroEscola de Ciências da Saúde e da Vida, Centro de Pesquisa em Toxicologia e Farmacologia, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga, 6681, Partenon, Porto Alegre, RS, 90619-900, Brazil.
Gabriel RübensamEscola de Ciências da Saúde e da Vida, Centro de Pesquisa em Toxicologia e Farmacologia, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga, 6681, Partenon, Porto Alegre, RS, 90619-900, Brazil.
Andressa BernardiFundação Oswaldo Cruz, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.ORCID http://orcid.org/0000-0002-4047-5807
Fernanda B MorroneEscola de Ciências da Saúde e da Vida, Laboratório de Farmacologia Aplicada, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil.ORCID http://orcid.org/0000-0002-2709-2801
Andre A SoutoEscola de Ciências da Saúde e da Vida, Programa de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil.ORCID http://orcid.org/0000-0002-2437-8767
Maria M CamposEscola de Ciências da Saúde e da Vida, Centro de Pesquisa em Toxicologia e Farmacologia, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga, 6681, Partenon, Porto Alegre, RS, 90619-900, Brazil.ORCID http://orcid.org/0000-0002-1153-3633
Pontifícia Universidade Católica do Rio Grande do Sul · BRFundação Oswaldo Cruz · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 304042/2018-8Conselho Nacional de Desenvolvimento Científico e Tecnológico 310317/2018-5Financiadora de Estudos e Projetos 01.11.0014-00
6 · The paper itself

Abstract

This study investigated the effects of systemic treatment with a new formulation of resveratrol (RSV) vehicled in rice oil (RSVO) in experimental rat models of inflammation. Male Wistar rats were evaluated in the following in vivo models: carrageenan-induced acute edema, complete Freund's adjuvant (CFA)-evoked sub-chronic edema, and CFA-induced polyarthritis. The animals were treated orally with RSVO (10-15 mg/kg) or RSV (100-200 mg/kg), depending on the experimental protocol. RSV was more effective than RSVO in carrageenan-elicited acute edema when dosed in either prophylactic or therapeutic schemes of administration. However, the repeated RSVO administration, at 10-fold lower doses, exhibited superior anti-inflammatory actions in either the sub-chronic edema or the chronic polyarthritis model elicited by CFA, when compared with RSV. The novel formulation RSVO displayed a lower plasma biotransformation when compared with the RSV-treated group-46% versus 88% of metabolites, respectively. RSVO also prevented polyarthritis-related cartilage destruction, an effect that might rely on the inhibition of the pro-inflammatory cytokine interleukin-6 (IL-6), associated with an increase of the anti-inflammatory cytokine interleukin-10 (IL-10). Noteworthy, the long-term administration of RSVO did not elicit any gastrointestinal harm. Our study revealed that RSVO was notably effective in the long-term inflammatory and degenerative responses triggered by CFA. This innovative formulation might well represent a promising alternative for treating chronic inflammatory diseases, such as arthritis.

Indexed as

AnimalsAnti-Inflammatory AgentsCarrageenanCytokinesDisease Models, AnimalDrug CompoundingFreund's AdjuvantInflammationInflammation MediatorsJointsMaleRats, WistarResveratrolRice Bran OilAnti-Inflammatory AgentsCarrageenanCytokinesFreund's AdjuvantInflammation MediatorsResveratrolRice Bran Oilacute and chronic inflammationcomplete Freund’s adjuvantpolyarthritisresveratrolresveratrol vehicled in rice oil

Identifiers

PMID31720991
OpenAlexW2986838257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.